Humedics Closes 6.3 Million€ Financing Round
Humedics GmbH has announced the closing of a Series C financing round totaling more than 6.3 million Euro. Humedics’ business model, products and company development has attracted new international investors that will join the current private and public investors.
The financing round was led by two new international investors, Vesalius Biocapital Partners and Seventure Partners. All venture capital investors from previous rounds are also participating in the present financing round.
The existing syndicate includes Peppermint Venture Partners (managing the Charité Biomedical Fund), VC Fonds Technologie managed by IBB-Beteiligungsgesellschaft, ERP Startfonds of the Kreditanstalt für Wiederaufbau (KfW), Ventegis and High-Tech Gründerfonds.
The raised capital will be used for the European market entry of Humedics’ proprietary LiMAx test and the corresponding FLIP diagnostic device. This breath test based diagnostic system represents a revolution in functional liver diagnostics by enabling clinicians to quantitatively determine the individual liver function capacity for a patient within minutes. It allows for better risk assessment in liver surgery and thus, superior surgery planning as well as selecting treatment strategies optimally adapted to the individual patients liver status. The LiMAx test provides certainty for the physician, safety for the patient and leads to cost reduction for the hospital.
Erwin de Buijzer, Managing Director of Humedics GmbH and private co-investor in the financing round, states: “We are delighted that we were able to attract international venture capital partners to join the consortium of investors; all of them are highly experienced in healthcare investments. The investment and the broad expertise of our investors establishes a sound basis for a successful application for marketing authorization of the LiMAx test in 2015. We are convinced that the LiMAx test contributes to optimized therapy of patients with acute and chronic liver failure and the LiMAx test has the potential to become a gold standard in liver diagnostics.”
The new investors will join the Humedics Board. Vesalius Managing Partner Dr. Christian Schneider and Dr. Robert Schier from Seventure Partners will reinforce the current board that consists of Dr. Klaus Stöckemann (Peppermint VenturePartners), Ute Mercker (IBB Beteiligungsgesellschaft) and Dr. Volker Pfahlert (Numares Group).